Pfizer, YaoPharma Partner on GLP-1 Drug for Weight Management

Pfizer has entered into a global collaboration and licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, to advance the development of YP05002, an investigational small-molecule GLP-1 receptor agonist being studied for chronic weight management. The companies announced the deal as interest in next-generation obesity therapies continues to surge worldwide.

YP05002, currently in Phase 1 clinical development, is designed to target the GLP-1 receptor pathway, a mechanism that has rapidly gained traction in the obesity and metabolic disorder treatment landscape. Unlike injectable GLP-1 therapies, YP05002 is a small-molecule candidate, positioning it as a potentially more convenient option for patients if approved.

Chris Boshoff, M.D., Ph.D., Chief Scientific Officer and President of Research & Development at Pfizer, said the partnership aligns with the company’s strategic emphasis on cardiometabolic innovation. “We look forward to contributing our expertise and resources to continue the development of this investigational GLP-1 small molecule which complements and strengthens our growing portfolio of novel candidates for treating obesity and its adjacent diseases,” Boshoff said. He added that cardiometabolic research remains a key growth priority for Pfizer.

Under the terms of the agreement, YaoPharma will complete the ongoing Phase 1 study of YP05002. Pfizer will receive exclusive global rights to further develop, manufacture, and commercialize the candidate. In return, YaoPharma will receive a $150 million upfront payment and is eligible for milestone payments that could total up to $1.935 billion upon achieving development, regulatory, and commercial milestones. The agreement also includes tiered royalties on future sales, pending regulatory approval.

Pfizer said it plans to explore combination regimens pairing YP05002 with other metabolic candidates in its pipeline, including PF-07976016, a GIPR antagonist now in Phase 2 clinical development. The company also indicated that additional combination studies may be considered as it advances its broader portfolio of small-molecule obesity therapies.

The collaboration underscores the pharmaceutical industry’s increasing investment in oral alternatives to current GLP-1-based therapies and reflects Pfizer’s ambition to strengthen its position in the competitive obesity drug market.